Semaglutide's paediatric approval status — separating fact from assumption

The misconception: a US approval for teenagers means it's available the same way in the UK

This is the source of most of the confusion. In late 2022, the US Food and Drug Administration approved Wegovy (semaglutide 2.4mg weekly) for chronic weight management in adolescents aged 12 and over with obesity. That decision was widely reported, and for readers in the UK it can look like a global shift in how this medicine is used. It isn't. The MHRA (the regulator responsible for authorising medicines in Great Britain) makes its own assessment independently of the FDA. A US paediatric approval creates no legal or clinical pathway to prescribing the same medicine to under-18s here. If you check the current NHS semaglutide page, it is unambiguous that this medicine is prescribed for adults. The UK licence has not been extended to cover younger patients for weight management, and no MHRA paediatric approval for this indication has been announced as of summer 2026. That boundary holds whether you approach a GP, a specialist or a private clinic.

It is also worth noting that the Wegovy UK approval history covers only adult populations. Any expansion to a younger age group would require a separate submission, a fresh MHRA assessment and (for NHS access) a new NICE appraisal process. None of those steps has been completed for a paediatric weight-management indication in the UK.

What the clinical trial data in adolescents actually shows

The STEP TEENS trial (published in the New England Journal of Medicine) randomised 201 adolescents aged 12 to 17, all with obesity, to either semaglutide 2.4mg weekly or placebo alongside lifestyle intervention over 68 weeks. The semaglutide group achieved an average BMI reduction of around 16% relative to baseline, compared with a roughly 0.6% increase in the placebo group, a statistically and clinically significant difference. Side effects followed the same gastrointestinal pattern seen in adults: nausea and vomiting were more common in the semaglutide group, generally mild to moderate and most pronounced at the start of treatment or after a dose increase. Discontinuation rates due to side effects were low but higher than in the placebo arm.

That evidence base is real and peer-reviewed. What it does not create is a prescription right. Trial participation and licensed clinical use are different things, and the STEP TEENS results have not, as yet, resulted in the MHRA granting a paediatric licence for this indication in the UK. For context on how semaglutide's adult evidence base evolved into a UK licence, the history of semaglutide's first approval shows the same multi-stage process: trial evidence, regulatory submission, assessment, licence grant.

Where adolescent weight management support is available in the UK right now

For children and teenagers living with obesity in England, the appropriate route is through NHS paediatric services. NHS England has specialist weight management programmes for younger patients that are separate from the adult tiered pathways. A GP referral is typically the starting point. These services can draw on a range of approaches including dietary support, psychological input and, where clinically appropriate, medicines that do hold a paediatric licence, a different consideration entirely from adult weight-loss injections.

Private online pharmacies, including ours, do not prescribe semaglutide or tirzepatide to anyone under 18. That is not a policy choice sitting above clinical judgement, it reflects the licensing position. Prescribing an unlicensed medicine to a minor for weight management would be outside the bounds of responsible clinical practice for an online independent prescriber. If you are looking at weight-loss treatment options for yourself as an adult, we can help; if the question relates to a young person in your family, the right conversation starts with their GP.

One useful habit: before relying on any report about a medicine becoming available for a new group of patients, it takes under a minute to check the MHRA's public register or the NHS medicines page for that drug. The NHS page is updated when licences change; if it still says adults only, that is the current position regardless of what has happened in the US, EU or anywhere else.

The semaglutide regulatory picture keeps moving. The medicine gained its first UK adult weight-management approval in 2021, and you can read more about the semaglutide approval date and the regulatory journey that brought it to market. A conditional approval for a form of liver disease came in July 2026, and the oral tablet was approved for UK adults in June 2026. Each of those was a separate MHRA decision. A paediatric weight-management indication would be another, and our page on Wegovy pediatric dosing considerations explains why the dose titration schedule studied in trials differs from the adult programme and why that matters for any future licensing discussion. For now, the adult licence is the one that governs private prescribing, and that is the population our clinical team assesses and treats.